The use of biological agents in the treatment of rheumatoid arthritis.
- Author:
Peng Thim FAN
;
Keng Hong LEONG
- Publication Type:Journal Article
- MeSH:
Abatacept;
Antibodies, Monoclonal;
therapeutic use;
Antibodies, Monoclonal, Humanized;
Antirheumatic Agents;
therapeutic use;
Arthritis, Rheumatoid;
immunology;
therapy;
Drug Therapy, Combination;
Humans;
Immunoconjugates;
therapeutic use;
Immunologic Factors;
adverse effects;
therapeutic use;
Immunosuppressive Agents;
therapeutic use;
Methotrexate;
therapeutic use;
Remission Induction;
Tumor Necrosis Factor-alpha;
antagonists & inhibitors
- From:Annals of the Academy of Medicine, Singapore
2007;36(2):128-134
- CountrySingapore
- Language:English
-
Abstract:
Rheumatoid arthritis is a common and potentially devastating condition which did not have good treatment options until recently. Pharmacological treatment should not just comprise antiinflammatory agents and corticosteroids. The current therapeutic approach is to start a disease modifying agent early in the illness to prevent eventual joint damage. Older disease modifying anti-rheumatic drugs (DMARDs) include methotrexate, sulphasalazine and hydroxychloroquine. Newer ones such as leflunomide and cyclosporine are also used. A recent advance in the management of rheumatoid arthritis is the use of biological agents which block certain key molecules involved in the pathogenesis of the illness. They include tumour necrosis factor (TNF)- blocking agents such as infliximab, etanercept and adalimumab, the anti-CD 20 agent rituximab and CTLA-4 Ig abatacept. Other agents which are in development include anti-IL6 tocilizumab, anti-CD22 and anti-lymphostat B. In this review, the efficacy and side effects of these agents, their impact on current clinical practice and future trends are discussed.
